title: Post-menopausal hormone therapy reduces autoantibodies to oxidized apolipoprotein B100.
abstract: The aim of the study was to verify whether post-menopausal hormone replacement therapy (HRT) modifies autoantibody titers against oxidized low-density lipoprotein (LDL) (anti-LDLoxi), against epitopes of oxidized apolipoprotein B100 and common carotid intima-media thickness (IMT) in these women. Sixty-eight women in pre-menopause (PMW) and 216 in post-menopause (POMW) were recruited; eighty-three had undergone HRT for at least 12 months, where 48 received conjugated estrogens alone (EHRT) and 35 received conjugated estrogen and medroxyprogesterone acetate (CHRT). ELISA was used to determine autoantibodies. Lipoprotein lipase (LPL), hepatic lipase (HL), cholesterol ester transfer protein (CETP) and phospholipid transfer protein (PLTP) activities were assayed by radiometric methods. IMT was measured using Doppler ultrasound. Anti-oxidized LDL and anti-D antibodies increased by 40% (p ≤ 0.003) and 42% (p ≤ 0.006), respectively, with menopause. There was a surprising and significant 7% reduction in anti-D2 antibody titers with HRT (p ≤ 0.050), indicating a positive effect of treatment on the immune response to oxidized LDL. Combined HRT decreased activities of HL and LPL. HRT did not change common carotid IMT, which was increased by 32% as expected after menopause (p ≤ 0.030). This study describes, for the first time, the protective effect of HRT on decreasing autoantibody titers against oxidized apolipoprotein B in LDL.
authors: Clinical Pathology Department, Faculty of Medical Sciences, /FCM/University of Campinas, São Paulo, Brazil.
authors: Vera Sylvia
authors: VS
authors: Castanho
authors: Magnus
authors: M
authors: Gidlund
authors: Rui
authors: R
authors: Nakamura
authors: Eliana Cotta
authors: EC
authors: de Faria
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D053299:Apolipoprotein B-100 / Q000037:antagonists & inhibitors* / Q000737:chemistry; D001323:Autoantibodies / Q000032:analysis*; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D017536:Carotid Artery, Common / Q000000981:diagnostic imaging / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D059168:Carotid Intima-Media Thickness; D000939:Epitopes; D015914:Estrogen Replacement Therapy / Q000379:methods; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008049:Lipase / Q000097:blood; D008071:Lipoprotein Lipase / Q000097:blood; D008077:Lipoproteins, LDL / Q000037:antagonists & inhibitors*; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D008593:Menopause / Q000187:drug effects* / Q000276:immunology; D008875:Middle Aged; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000187:drug effects*
chemical_list: D053299:Apolipoprotein B-100; D001323:Autoantibodies; D000939:Epitopes; D004966:Estrogens, Conjugated (USP); C504173:LIPC protein, human; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D017258:Medroxyprogesterone Acetate; D008049:Lipase; C548261:LPL protein, human; D008071:Lipoprotein Lipase